Geneious Biologics, an enterprise software solution for companies engaged in screening of antibodies and antibody-like
molecules, has been selected by FairJourney Biologics, a leading contract research organization (CRO), to support the
company’s growth as it incorporates increasingly large Sanger data sets and next-generation sequencing (NGS) into its
discovery programs.
Geneious Biologics is Biomatters’ cloud-based enterprise software for analysis of antibodies and related constructs
using DNA sequence data. The software applies intuitive visualization tools and advanced analytics to help specialist
biologic drug development companies accelerate identification of therapeutic candidates.
Geneious Biologics was selected by FairJourney Biologics for its ability to automate analysis and quality control (QC)
with accurate identification of relevant regions, sequence liabilities, errors and frame shifts.
“We are processing increasingly larger sets of antibody sequences,” said Daniela Teixeira, COO, FairJourney Biologics.
“Geneious Biologics allows us to drill into huge antibody sequence sets and quickly identify where errors lie and
inspect bad clones. This will ensure we return the most effective, stable therapeutic antibody candidates to our
clients, faster.”
“We are excited that FairJourney Biologics is preparing for growth and future-proofing its discovery efforts with
Geneious Biologics. There is a step change happening in the therapeutic antibody discovery industry as leading research
enterprises like FairJourney Biologics leverage the power of high throughput antibody sequencing,” said Jannick
Bendtsen, Vice President of Technology Services, Geneious Biologics.
“Our focus is building the world’s most robust and functional sequence analysis platform to help our customers deliver
quicker, more accurate results and identify therapeutic antibody candidates faster.”